| First Author | Larson RC | Year | 1994 |
| Journal | Oncogene | Volume | 9 |
| Issue | 12 | Pages | 3675-81 |
| PubMed ID | 7970726 | Mgi Jnum | J:22065 |
| Mgi Id | MGI:69956 | Citation | Larson RC, et al. (1994) T cell tumours of disparate phenotype in mice transgenic for Rbtn-2. Oncogene 9(12):3675-81 |
| abstractText | RBTN2 is a LIM domain protein which can be activated by the translocation t(11;14)(p13;q11) in childhood T cell acute leukaemia. Transgenic mice were examined in which rbtn2 protein is expressed in the T cell lineage. An average of 72% of these mice developed T cell tumours before 18 months of age, compared with 9% in transgenic mice expressing the related gene Rbtn-1. Rbtn2-induced tumours first appeared at 5 months of age and were clonal. They displayed a range of phenotypes, the most notable being CD3/CD45R double-positive cells. Tumours expressing either T cell receptor alpha/beta or gamma/delta heterodimers were found. Thus rbtn2 can promote tumours within a range of T cell types and maturities. The latency period before tumour development indicates that secondary events must occur before the onset of overt malignancy. |
